← Back to Search

Sodium Channel Blocker

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Phase 2
Waitlist Available
Led By Jeffrey Statland, MD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to week 12
Awards & highlights
Approved for 5 Other Conditions
No Placebo-Only Group
All Individual Drugs Already Approved

Summary

This trial will study whether Ranolazine is safe and effective for treating ALS patients.

Eligible Conditions
  • Lou Gehrig's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Dose Limiting Toxicities (DLT)
Secondary study objectives
Percent Change in Cramp Frequency
Percentage Change in Average Weekly Cramp Severity

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Ranolazine 500mgExperimental Treatment1 Intervention
Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
Group II: Ranolazine 1000mgExperimental Treatment1 Intervention
Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ranolazine
FDA approved
Ranolazine
FDA approved

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
517 Previous Clinical Trials
177,284 Total Patients Enrolled
Gilead SciencesIndustry Sponsor
1,137 Previous Clinical Trials
867,969 Total Patients Enrolled
Jeffrey Statland, MDPrincipal InvestigatorUniversity of Kansas Medical Center
5 Previous Clinical Trials
1,296 Total Patients Enrolled
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top